BACKGROUND: Prion protein (PrPc) has been previously reported to be associated with resistance to proapoptotic stimuli. We evaluated whether the expression of PrPc was associated with the resistance to adjuvant chemotherapy in patients with estrogen receptor (ER) -negative breast cancer. PATIENTS AND METHODS: The expression of PrPc by primary tumors was assessed by immunohistochemistry in a series of 756 patients included in two randomized trials that compared anthracycline-based chemotherapy to no chemotherapy. The PrPc expression was correlated with ER expression and the benefit of adjuvant chemotherapy was assessed according to PrPc expression in patients with ER-negative tumors. RESULTS: Immunostaining analysis showed that PrPc was mainly expressed by myoepithelial cells in normal breast tissue. Tissue microarray analysis from 756 breast tumors showed that PrPc was associated with ER-negative breast cancer subsets (P < 0.001). Adjuvant chemotherapy was not associated with a significant risk reduction for death in patients with ER-negative/PrPc-positive disease [adjusted hazard ratio (HR) for death = 0.98, 95% confidence interval (CI) 0.45-2.1, P = 0.95], while it decreased the risk for death (HR = 0.39, 95% CI 0.2-0.74, P = 0.004) in patients with ER-negative/PrPc-negative tumors. CONCLUSION: These data indicate that ER-negative/PrPc-negative phenotype is associated with a high sensitivity to adjuvant chemotherapy.
BACKGROUND:Prion protein (PrPc) has been previously reported to be associated with resistance to proapoptotic stimuli. We evaluated whether the expression of PrPc was associated with the resistance to adjuvant chemotherapy in patients with estrogen receptor (ER) -negative breast cancer. PATIENTS AND METHODS: The expression of PrPc by primary tumors was assessed by immunohistochemistry in a series of 756 patients included in two randomized trials that compared anthracycline-based chemotherapy to no chemotherapy. The PrPc expression was correlated with ER expression and the benefit of adjuvant chemotherapy was assessed according to PrPc expression in patients with ER-negative tumors. RESULTS: Immunostaining analysis showed that PrPc was mainly expressed by myoepithelial cells in normal breast tissue. Tissue microarray analysis from 756 breast tumors showed that PrPc was associated with ER-negative breast cancer subsets (P < 0.001). Adjuvant chemotherapy was not associated with a significant risk reduction for death in patients with ER-negative/PrPc-positive disease [adjusted hazard ratio (HR) for death = 0.98, 95% confidence interval (CI) 0.45-2.1, P = 0.95], while it decreased the risk for death (HR = 0.39, 95% CI 0.2-0.74, P = 0.004) in patients with ER-negative/PrPc-negative tumors. CONCLUSION: These data indicate that ER-negative/PrPc-negative phenotype is associated with a high sensitivity to adjuvant chemotherapy.
Authors: M H Lopes; T G Santos; B R Rodrigues; N Queiroz-Hazarbassanov; I W Cunha; A P Wasilewska-Sampaio; B Costa-Silva; F A Marchi; L F Bleggi-Torres; P I Sanematsu; S H Suzuki; S M Oba-Shinjo; S K N Marie; E Toulmin; A F Hill; V R Martins Journal: Oncogene Date: 2014-08-25 Impact factor: 9.867
Authors: Fabrice Andre; Lisa M McShane; Stefan Michiels; David F Ransohoff; Douglas G Altman; Jorge S Reis-Filho; Daniel F Hayes; Lajos Pusztai Journal: Nat Rev Clin Oncol Date: 2011-03 Impact factor: 66.675
Authors: Adrian P Wiegmans; Jodi M Saunus; Sunyoung Ham; Richard Lobb; Jamie R Kutasovic; Andrew J Dalley; Mariska Miranda; Caroline Atkinson; Simote T Foliaki; Kaltin Ferguson; Colleen Niland; Cameron N Johnstone; Victoria Lewis; Steven J Collins; Sunil R Lakhani; Fares Al-Ejeh; Andreas Möller Journal: JCI Insight Date: 2019-02-26